These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 17511025)

  • 1. Cyclooxygenase-2 expression after preoperative chemoradiotherapy correlates with more frequent esophageal cancer recurrence.
    Yoshikawa R; Fujiwara Y; Koishi K; Kojima S; Matsumoto T; Yanagi H; Yamamura T; Hashimoto-Tamaoki T; Nishigami T; Tsujimura T
    World J Gastroenterol; 2007 Apr; 13(16):2283-8. PubMed ID: 17511025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer.
    Kulke MH; Odze RD; Mueller JD; Wang H; Redston M; Bertagnolli MM
    J Thorac Cardiovasc Surg; 2004 Jun; 127(6):1579-86. PubMed ID: 15173710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of cyclooxygenase-2 is associated with chemoradiotherapy resistance and prognosis in esophageal squamous cell carcinoma patients.
    Huang WZ; Fu JH; Wang DK; Hu Y; Liu MZ; Yang H; Feng YF; Zheng B; Wang G; Luo KJ; Wen J; Rong TH
    Dis Esophagus; 2008; 21(8):679-84. PubMed ID: 18459994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of cyclooxygenase-2, vascular endothelial growth factor, and epidermal growth factor receptor in Chinese patients with esophageal squamous cell carcinoma.
    Cui Y; Dong C; Wu BQ; Duan XC; Shi G; Gong M; Wang TY
    J Cancer Res Ther; 2015 Aug; 11 Suppl 1():C44-8. PubMed ID: 26323923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VEGF as a predictor for response to definitive chemoradiotherapy and COX-2 as a prognosticator for survival in esophageal squamous cell carcinoma.
    Yoon MS; Nam TK; Lee JS; Cho SH; Song JY; Ahn SJ; Chung IJ; Jeong JU; Chung WK; Nah BS
    J Korean Med Sci; 2011 Apr; 26(4):513-20. PubMed ID: 21468258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent CXCR4 expression after preoperative chemoradiotherapy predicts early recurrence and poor prognosis in esophageal cancer.
    Koishi K; Yoshikawa R; Tsujimura T; Hashimoto-Tamaoki T; Kojima S; Yanagi H; Yamamura T; Fujiwara Y
    World J Gastroenterol; 2006 Dec; 12(47):7585-90. PubMed ID: 17171785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer.
    Xi H; Baldus SE; Warnecke-Eberz U; Brabender J; Neiss S; Metzger R; Ling FC; Dienes HP; Bollschweiler E; Moenig S; Mueller RP; Hoelscher AH; Schneider PM
    Clin Cancer Res; 2005 Dec; 11(23):8341-7. PubMed ID: 16322294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hedgehog signal activation in oesophageal cancer patients undergoing neoadjuvant chemoradiotherapy.
    Yoshikawa R; Nakano Y; Tao L; Koishi K; Matsumoto T; Sasako M; Tsujimura T; Hashimoto-Tamaoki T; Fujiwara Y
    Br J Cancer; 2008 May; 98(10):1670-4. PubMed ID: 18475300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy.
    Chao YK; Chan SC; Liu YH; Chen HW; Wan YL; Chang HK; Fan KH; Liu HP
    Ann Surg; 2009 Mar; 249(3):392-6. PubMed ID: 19247024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy.
    Cheng JC; Graber MS; Hsu FM; Tsai CL; Castaneda L; Lee JM; Chang DT; Koong AC
    Ann Surg Oncol; 2014 Jul; 21(7):2361-8. PubMed ID: 24623035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of COX-2 for the effect of chemoradiotherapy on esophageal squamous cell carcinoma.
    Takatori H; Natsugoe S; Okumura H; Matsumoto M; Ishigami S; Owaki T; Aikou T
    Oncol Rep; 2005 Apr; 13(4):697-701. PubMed ID: 15756444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma.
    Hashimoto J; Kato K; Ito Y; Kojima T; Akimoto T; Daiko H; Hamamoto Y; Matsushita H; Katano S; Hara H; Tanaka Y; Saito Y; Nagashima K; Igaki H
    Int J Clin Oncol; 2019 Jan; 24(1):60-67. PubMed ID: 30109544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is There a Correlation Between Clinical Complete Response and Pathological Complete Response After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Cancer?
    Liu SL; Xi M; Yang H; Yang YD; Wu YJ; Zhao L; Zhang P; Luo LL; Liu MZ
    Ann Surg Oncol; 2016 Jan; 23(1):273-81. PubMed ID: 26215200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic histological factors in patients with esophageal squamous cell carcinoma after preoperative chemoradiation followed by surgery.
    Tu CC; Hsu PK; Chien LI; Liu WC; Huang CS; Hsieh CC; Hsu HS; Wu YC
    BMC Cancer; 2017 Jan; 17(1):62. PubMed ID: 28103913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage lymphadenectomy versus salvage radiotherapy/chemoradiotherapy for recurrence in cervical lymph node after curative resection of esophageal squamous cell carcinoma.
    Ma X; Zhao K; Guo W; Yang S; Zhu X; Xiang J; Zhang Y; Li H
    Ann Surg Oncol; 2015 Feb; 22(2):624-9. PubMed ID: 25155397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear Localization of DNAJB6 Is Associated With Survival of Patients With Esophageal Cancer and Reduces AKT Signaling and Proliferation of Cancer Cells.
    Yu VZ; Wong VC; Dai W; Ko JM; Lam AK; Chan KW; Samant RS; Lung HL; Shuen WH; Law S; Chan YP; Lee NP; Tong DK; Law TT; Lee VH; Lung ML
    Gastroenterology; 2015 Dec; 149(7):1825-1836.e5. PubMed ID: 26302489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma.
    Akutsu Y; Hanari N; Yusup G; Komatsu-Akimoto A; Ikeda N; Mori M; Yoneyama Y; Endo S; Miyazawa Y; Matsubara H
    Ann Surg Oncol; 2011 Oct; 18(10):2946-51. PubMed ID: 21437756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. REG1A expression status suggests chemosensitivity among advanced thoracic esophageal squamous cell carcinoma patients treated with esophagectomy followed by adjuvant chemotherapy.
    Sato Y; Motoyama S; Nanjo H; Ito S; Yoshino K; Sasaki T; Kuribayashi K; Nagaki Y; Imai K; Saito H; Minamiya Y; Ogawa J
    Ann Surg Oncol; 2013 Sep; 20(9):3044-51. PubMed ID: 23645481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of weekly docetaxel combined with preoperative radiotherapy for locally advanced esophageal cancer from pathological analysis.
    Kushida T; Nohara S; Yoshino K; Fujiwara D; Ouchi K; Amano T; Isayama F; Tomita N; Iwanuma Y; Sasai K; Tsurumaru M; Kajiyama Y
    Dis Esophagus; 2014; 27(4):368-73. PubMed ID: 23865505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiRNA Expression Analysis of Pretreatment Biopsies Predicts the Pathological Response of Esophageal Squamous Cell Carcinomas to Neoadjuvant Chemoradiotherapy.
    Wen J; Luo K; Liu H; Liu S; Lin G; Hu Y; Zhang X; Wang G; Chen Y; Chen Z; Li Y; Lin T; Xie X; Liu M; Wang H; Yang H; Fu J
    Ann Surg; 2016 May; 263(5):942-8. PubMed ID: 26445467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.